- Active not recruitingPHASE2
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
This study allows people already getting certain cancer treatments through a Novartis trial to continue their treatment. It looks at how safe and effective these treatments are over a longer time for people with advanced solid tumours, giving them ongoing access to care.
For: Advanced Solid Tumors Which Are cMET-dependentUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
This study looks at new ways to treat advanced non-small cell lung cancer with a specific genetic change. It aims to see if combining a drug called ramucirumab with existing treatments like erlotinib, gefitinib, or osimertinib can work better than current approaches.
For: Metastatic Non-Small Cell Lung CancerUnited States · Canada · France